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Abstract 
Merkel cell carcinoma (MCC) typically presents as an isolated cutaneous lesion with a 
measurable risk of regional lymph node involvement. Uncommonly, synchronous or 
metachronous lesions have been described to be attributed to a field effect. This case 
report describes a patient presenting with metachronous lesions, separated by several 
years, which cannot be attributed to a field effect given the tumor distribution. 
 
Introduction 
Merkel cell carcinoma (MCC) is an uncommon cutaneous malignancy with an 
estimated 1,500 cases diagnosed annually in the US. It is most commonly seen in men in 
their 70s and on sun-exposed skin. Moreover, when it is found in immunosuppressed 
patients, the clinical course can be more fulminant [1]. The cell of origin remains elusive 
and the non-descript nature of the histology has led to various descriptions of the tumor, 
which include small cell cancer of the skin, trabecular cutaneous tumor, or anaplastic skin 
cancer [2]. Although the regional lymph nodal basin may be occultly involved in as many 
as 24% of cases at presentation [3], and hematogenous spread is well documented and is 
importantly linked to overall survival [4], simultaneous or synchronous [5] presentation 
of the cutaneous lesion is unusual. Even more odd than what may be explained as a 
regional field effect causing adjacent simultaneous lesions is the process of metachronous 
cutaneous lesions, particularly when the presentation is disparate in location. Herein, we 
present a case report of the metachronous presentation of MCC. 
Case Presentation 
We present the case of a male patient who first presented to medical attention in September 2005, 
when he was 67 years of age. He complained of a pea-sized, non-erythematous, non-pruritic lesion Case Rep Dermatol 2011;3:206–208 
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overlying the medial compartment of the left infrapatellar leg. An excisional biopsy revealed a 2.5-cm 
focus of MCC with microscopic margin involvement. He was seen by one of the authors (E.P.P.) who 
re-excised the lesion and performed a sentinel node staging simultaneously. The re-excision revealed a 
remnant 1.1 cm of tumor with negative margins. The sentinel node procedure revealed 2 nodes 
involving the superficial groin, both of which contained metastatic disease. A second stage groin 
dissection was conducted which failed to reveal further metastatic disease. The patient underwent 
staging studies, including a contrast-enhanced CT scan of his chest, abdomen, and pelvis, which showed 
no evidence of metastatic disease. Given the regional nodal involvement and the neuroendocrine nature 
of the tumor, the patient was recommended adjuvant cisplatin and etoposide chemotherapy, and he 
completed 4 cycles. He then received complete 5,600 cGy of external electron beam teletherapy to the 
tumor bed plus a 2-cm margin. His treatment course was essentially uncomplicated.  
He had been followed closely on a quarterly basis with clinical examinations and annual chest 
radiography when, in November 2008, he developed a cystic and erythematous lesion overlying the 
right olecranon process (fig. 1). 
He visited his plastic surgeon, and an excisional biopsy demonstrated a 1-cm focus of MCC with a 
close deep margin. He underwent a re-excision and sentinel node mapping, revealing no residual local 
disease and negative regional axillary nodes. A staging CT-PET fusion failed to reveal metastatic disease. 
Treatment with 5,000-cGy electron beam teletherapy to the tumor bed was continued, completing that 
course uneventfully. The patient’s medical history was notable for osteoarthritis, osteoporosis, 
hyperlipidemia, hypertension, cardiac dysrhthymia, and vascular disease. Medications included 
Celebrex, Fosomax, KCl, Diovan, Toprol, Vytorin, Coumadin, Norvasc, and Tramadol. His family 
history was notable for a brother who died of a primary brain tumor and a daughter who had a 
rhabdomyosarcoma. He was a retired carpenter who consumed alcohol socially and did not use tobacco 
products. He denied excessive sun exposure. 
Discussion 
This patient example of a metachronous MCC represents a distinct entity. To our 
knowledge, only one previous case report of a metachronous MCC has been reported in 
the literature and those authors concluded that the second occurrence represented a field 
defect given the proximity of the two tumors as well as a sophisticated DNA comparison 
linking the lesions to the same cellular precursor [6]. When metachronous lesions of a 
rare malignancy occur, the clinician is obligated to pursue an underlying cause. There are 
no known risk factors associated with the development of MCC, and this malignancy is 
not associated with any known genetic family of cancers. A family history of a brain 
tumor and sarcoma suggests a potential Li-Fraumeni syndrome, though this rare 
mutation in the p53 gene has not been associated with MCC. Immunosuppression has 
been shown to increase the likelihood of unifocal MCC [7]; however, it has not been 
reported to increase the risk of metachronous lesions, nor does this patient have any 
history of conventional forms of immunosuppression. Several studies have suggested a 
role for polyomavirus in the etiology of MCC, and virus-specific assays assess the 
involvement of the infectious agent [8]. The patient presented in this report had no 
clinical manifestations of this virus, but a specific assay was not performed, leading us to 
query whether his metachronous presentation of MCC was virus-induced. Indeed, 
addressing the specific clonal rearrangement of the two separate lesions may have added 
to the evidence that the two tumors were related (perhaps in their viral association) or 
truly separate. Although it is tempting to identify a potential viral pathogen that may be 
associated with MCC, the development of an anti-viral therapy or immunization remains 
of scientific import only for the present and perhaps, because of the rarity of MCC, will 
never become a practical consideration. Because of the potential increase in risk that this 
patient may develop future disparate MCC lesions, regardless of the etiology, he is being Case Rep Dermatol 2011;3:206–208 
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followed closely with clinical dermatologic surveys. Other surveillance studies, such as 
laboratory or radiographic surveys, appear unwarranted in the absence of signs or 
symptoms of disease. 
 
 
 
 
 
 
Fig. 1. Cystic and erythematous lesion overlying the right olecranon process. 
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